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ABSTRACT 
 
Background 
This case represents an exceptional response to pembrolizumab in a patient with 
epithelioid mesothelioma with a further response on rechallenge.  
Case presentation 
A 77 year old woman with advanced epithelioid mesothelioma extensively pretreated 
with chemotherapy demonstrated a prolonged response of 45 months to 52 cycles of 
pembrolizumab. On rechallenge with pembrolizumab further disease stability was 
achieved. Serial biopsies and analysis by immunohistochemistry and 
immunofluorescence demonstrated marked immune infiltration and documents the 
emergency of markers of immune exhaustion. Whole exome sequencing 
demonstrated a reduction in tumour mutational burden consistent with sub-clone 
elimination by immune checkpoint inhibitor (CPI) therapy. The relapse biopsy had 
missense mutation in BTN2A1.  
Conclusion 
This case supports rechallenge of PD-1 inhibitor in cases of previous CPI sensitivity 
and gives molecular insights. 
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BACKGROUND 
Mesothelioma is a rare cancer of the pleura and mesothelial membranes associated 
with asbestos exposure and a poor prognosis. Subtypes include epithelioid, biphasic 
and sarcomatoid. A multimodal approach that may include surgery, radiotherapy and 
chemotherapy is often attempted for potentially resectable disease but a proven 
survival benefit has not, as yet, been demonstrated [1].   The majority of patients have 
inoperable disease. Treatment for inoperable disease has previously been with  
chemotherapy though with relatively poor rates and duration of response novel 
therapeutic strategies are required [2]. Recent trials have assessed the utility of CPI. 
The documentation of responses suggest that mesothelioma is a relatively 
“immunogenic” tumour. [3] [4] Pembrolizumab is an anti-programme death receptor 1 
(PD-1) antibody investigated in mesothelioma. KEYNOTE-028 recruited 25 patients 
with PD-L1 positive pleural mesothelioma and has reported interim results; objective 
response rate of 20%,  disease control rate of 52% and a median duration of response 
of 12.0 months (95% confidence interval of 3.7 – not reached). [5]  
 
 
 
CASE PRESENTATION 
Clinical Background 
The patient is a 77 year old Caucasian woman. She was diagnosed with a left 
epithelioid mesothelioma on video-assisted thorascopic biopsy in 2009 with pleurally 
based nodules in the left hemothorax on radiological assessment. She underwent talc 
pleurodesis and four cycles of cisplatin and pemetrexed. Sixteen months later she 
developed progressive disease and was treated on a trial of NGR-hTNF (a selective 
vascular inhibitor) for four months to disease progression. She underwent rechallenge 
with four cycles of pemetrexed and cisplatin; achieving disease stability for 11 months. 
She then received six cycles of carboplatin and gemcitabine achieving disease 
stability for six months.  
 
From June 2014 to June 2016 she received 52 cycles of pembrolizumab (MK-3475) 
at a dose of 10mg/kg every two weeks on a phase Ib clinic trial (KEYNOTE-028). The 
tumour biopsy fulfilled criteria for PD-L1 positivity as per trial protocol. She tolerated 
drug well with immune-related adverse events of grade 2 pruritic rash and grade 1 
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mucositis, remaining ECOG performance status 1. A partial response was seen on 
imaging after 3 months, with a 91% reduction in target lesions, that was maintained 
until June 2016 (figure 1). In April 2018, 21 months after completing two years of 
pembrolizumab, she developed asymptomatic, small volume, radiological disease 
progression and recommenced pembrolizumab on study, per protocol, on the same 
schedule. Following 3 cycles a 12% reduction in tumour size by RECIST criteria from 
the pre-rechallenge baseline was seen . Stable disease was maintained for 25 cycles 
when radiological disease progression was confirmed.   
 
 
Laboratory correlates of immune response 
A left pleural biopsy from 2014, taken as baseline biopsy for KEYNOTE-028, and a 
left pleural biopsy taken in 2018 at relapse prior to pembrolizumab rechallenge were 
analysed. Histopathology was consistent with malignant epithelioid mesothelioma with 
cells expressing WT1, calretinin and HBME-1 and negative for BerEP4.  
 
Immunohistochemistry for PD-L1 was performed using Dako 22C3 and Ventana 
SP263 clones (supplementary data for methods). PD-L1 staining was increased in the 
relapse compared to baseline biopsy (1-49% in relapse biopsy by SP263, Figure 2).  
 
CD3 immunohistochemistry was performed on baseline and relapse biopsies and 
intensity of staining quantified using the HALO software (supplementary data for 
methods).  Intratumoural T-cells were of a higher density in the relapse compared to 
baseline biopsy (2092.06/mm2 versus 348.53/mm2) (figure 2). 
 
A T-Cell Panel immunofluorescence panel for CD4, CD4+FOXP3+, CD8 and PanCK 
(pancytokeratin) was performed and analysed with inForm Cell Analysis software 
(supplementary data for methods). Intratumoural CD8 T-cells demonstrated an almost 
5-fold increase in relapse compared to baseline biopsy and CD4+FOXP3+ T-cells 
demonstrated over a 30-fold increase in relapse compared to baseline (table 1, figure 
3).  
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T-cell Subset Baseline biopsy (2014) Relapse biopsy (2018) 
CD4 172.03 113.13 
CD4+FOXP3+ 2.62 88.89 
CD8 128.60 565.67 
All T-cells 303.26 767.69 
Table 1. Intratumoural T-cell density (per mm2) on baseline and relapse biopsy 
by immunofluorescence. 
 
 
Genomics 
Whole exome sequencing (WES) was performed on both biopsy samples and a 
matched germline sample (supplementary data for methods). Tumour content was 
80%. The baseline biopsy had 0.92 somatic mutations per Mbp. The relapse biopsy 
had 0.26. No mutations were found in key drivers such as BAP1, NF2, TP53, LATS2 
and SETD2. On copy number variant (CNV) analysis copy number alterations (CNA) 
were apparent mostly similar in frequently altered genomic region between baseline 
and relapse biopsy such as chr8q gain, and chr3p and chr9p loss, but also some 
regions were different such as loss of heterozygosity on chr6q and chr4q in baseline 
only (figure 4). Three independent measurements of genomic instability (basis of loss 
of heterozygosity, telomeric allelic imbalance, and large-scale state transitions) shows 
baseline biopsy had instable genome with higher HRD score. Immune related somatic 
mutations are detailed in table 2. All immune related somatic mutations present in the 
baseline biopsy were not present in the relapse biopsy. The relapse biopsy had 
missense mutation in BTN2A1 (c.1352G>C).  
 
 
Sample Gene 
Name 
HGVS Mutation Effect TUMOR 
Alternative Allele 
Depth/Sequencing 
Depth 
Allele 
Frequency 
Baseline MST1 c.1423+1->CC Splice_Site 18/103 0.17 
PROS1 c.1030A>G Missense_Mutation 26/132 0.2 
NLGN1 c.1504_1505insC Frame_Shift_Ins 12/194 0.06 
NLGN1 c.1507delG Frame_Shift_Del 12/204 0.06 
MUC4 c.5420T>C Missense_Mutation 29/657 0.04 
TDP2 c.1037G>A Missense_Mutation 41/155 0.26 
MUC17 c.8179G>A Missense_Mutation 12/464 0.03 
VWF c.1060G>A Missense_Mutation 12/289 0.04 
MAG c.1388C>T Missense_Mutation 12/662 0.02 
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LILRB2 c.50C>G Missense_Mutation 12/55 0.22 
PREX1 c.1489G>A Missense_Mutation 12/381 0.03 
Progression BTN2A1 c.1352G>C Missense_Mutation 11/92 0.12 
Table 2: Immune related somatic mutations on baseline and relapse biopsy.  
 
 
DISCUSSION AND CONCLUSION 
 
Dynamic immune changes and changes in tumour mutational burden (TMB) 
map the clinical response to pembrolizumab 
The differences seen in levels of T-cell infiltration between the two biopsies in this 
patient demonstrate the dynamic changes that occur in the context of CPI treated 
malignancy. Three cancer-immunity phenotypes have been described. The first is 
“immune desert”, which can be a result of tolerance, immunological ignorance or lack 
of priming. In this situation no immune response is mounted to the cancer and little T-
cell infiltration is seen. The second is the “immune excluded” tumour in which there is 
a barrier to immune cell migration to tumour caused by stromal interactions, vascular 
barrier and, again, no T-cell infiltration is demonstrated. Thirdly, the “inflamed” tumour 
demonstrate infiltration by immune cells. Inhibitory factors (e.g. PD-L1) and T-cell 
exhaustion may still impair anticancer immunity in this setting. [6] T-cell exhaustion 
describes a progressive loss of T-cell function occurring on persistent antigen 
presentation. [7] Relapse biopsies in this patient demonstrate increased immune cell 
infiltrate of CD3 CD8 and CD4 T-cells, compared to baseline. This is indicative of 
immune activation as a result of the primary immunotherapy treatment (a move from 
an immune desert to inflamed tumour) and is consistent with the prolonged response. 
However, there is also an increase in FOXP3 positive T-cell, a marker of regulatory T-
cells, and PD-L1. Therapeutic targeting of PD-1 is known to effect regulatory T-cell 
function but not overall number [8]. We may consider the increase in regulatory T-cells 
a marker of immune exhaustion.  These markers of immune exhaustion represent 
emerging resistance to immunotherapy as evidenced by the clinical progression. 
Despite these markers of immune exhaustion a response to pembrolizumab 
rechallenge was achieved thus resistance to immunotherapy was not complete. The 
finely tuned balance of immunostimulatory and immunosuppressive elements 
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demonstrated in these sequential biopsies in combination with the radiological data 
present a compelling visualisation of immune activation and exhaustion and clinical 
implications. A disadvantage of this study is that single biopsies were taken and there 
may be  heterogeneity of immune infiltrates throughout the tumour burden. Ongoing 
trials address the potential in mesothelioma for drug combinations to move tumours to 
the inflamed phenotype and overcome CPI resistance. Preclinical evidence suggests 
chemotherapy causes a degree of immune activation [9] and studies propose rational 
combination and sequencing of chemotherapy and CPI to achieve this end. The phase 
II DREAM study of durvalumab in combination with pemetrexed and cisplatin gave an 
objective treatment response rate of 48% and a phase III is planned [10]. 
 
The reduction in the number of somatic mutations between two samples can suggest 
subclones eliminated by pembrolizumab. This phenomenon is well described 
previously in melanoma patients treated with nivolumab. [11]  On treatment with CPI 
immunoediting occurs where tumour cells expressing neoantigens targeted by 
activated T-cells are lost. [12] The resulting loss of cancer heterogeneity results in 
more homogenous cancer cell population and a lower rate of somatic mutations and 
a lower TMB.  
 
The case in context as a long-term responder to pembrolizumab and 
chemotherapy 
What is remarkable about this patient’s initial response is the depth and duration. The 
relapse of disease occurred 21 months after the last dose of pembrolizumab. A recent 
paper suggests nivolumab can be detected more than 20 weeks following 
administration which is longer than might be anticipated from previous 
pharmacokinetic data. [13]. Nevertheless the relapse in this patient occurred long after 
the elimination of all residual drug. Most CPI trials demonstrate a “tail to the curve” 
with a small number of patients who achieve a prolonged response. [14] Study of these 
“exceptional responders” can potentially inform on biological features that mark 
prolonged response and be hypothesis generating for further research into 
mechanisms of drug resistance and sensitivity.  
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WES results reveal a TMB low tumour. Mesothelioma is classically a TMB low tumour. 
Analysis of 74 cases revealed a somatic mutation rate of less than 2 per megabase in 
all but one case. [15] Also, in keeping with published data is the CNA seen in this case. 
Others report frequent CNA in keeping with mesothelioma being driven by loss of 
tumour suppressors rather than an oncogenic driven cancer. [15] Transcriptome 
analysis was not performed. Others have identified expression of the negative 
checkpoint inhibitor VISTA commonly in mesothelioma which may have implications 
on CPI response. [15] 
 
Proposed resistance mechanisms to CPI are numerous and may be multifactorial. [16] 
The only immune related mutated gene evidenced in the relapse biopsy was BTN2A1. 
This is a T cell immunomodulatory molecule coregulated with MHC class II.[17] It’s 
role in CPI resistance is not described. As the BTN2A mutation was seen on the 
relapse biopsy (post relapse but pre rechallenge) the implications of the mutation (if 
any) is unclear; whether having a role in emerging resistance or sensitivity to 
rechallenge.  
 
It is also interesting to consider the patient’s prior response to chemotherapy. She 
achieved an unusual (though not unique) 16 month progression free survival with first-
line cisplatin-pemetrexed chemotherapy and further response on two chemotherapy 
rechallenges. The phase II MAPS2 trial of nivolumab or nivolumab-ipilimumab in 
relapsed mesothelioma included an post hoc analysis showing that in the nivolumab 
group patients who had relapse at least 3 months after pemetrexed-chemotherapy 
had a small survival benefit [18]. Whether these findings are replicated in other trials 
and whether this simply represents a more globally indolent disease or whether there 
is a biological rationale for chemotherapy response correlating with benefit from CPI 
remains to be seen.   
 
The case in context as a response to pembrolizumab rechallenge 
This patient’s cancer is also exceptional in its responsiveness to pembrolizumab on 
rechallenge. This phenomena has not be studied in detail. Though others report the 
potential for a response with CPI rechallenge,[19] this is the first report, to our 
knowledge, of disease response on CPI rechallenge in mesothelioma. 
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Conclusion 
In conclusion, this case represents a prolonged response to pembrolizumab in a 
patient with epithelioid mesothelioma to PD-1 inhibition with further durable clinical 
benefit on rechallenge. This supports trial data from Keynote-028 and others that 
mesothelioma can be responsive to CPI. In this case no reason for prolonged immune 
sensitivity was identified. The tumour, though PD-L1 positive, did not demonstrate a 
very high level of  PD-L1 expression. WES did not shed light on reasons for prolonged 
sensitivity to CPI; chromothripsis and loss of heterozygosity are not fully assessed on 
WES and epigenetic modifications such as methylation are not evaluated by WES.  
 
Serial biopsies demonstrate both the primary immune activation and emerging 
immune exhaustion. Future research may shed light on the mechanisms of resistance 
and pave the way for drug combinations to overcome CPI resistance. Cases such as 
this support attempts to retreat with CPI if a patient clinical condition allows. Further 
research into the degree to which a “partially exhausted” immune environment can be 
reactivated by further stimulation are warranted. 
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ABBREVIATIONS 
BAP1     BRCA1 associated protein-1  
BTN2A1     Butyrophilin Subfamily 2 Member A1 
CD     Cluster of differentiation 
CK     Cytokeratin 
CAN     Copy number aberration 
CPI    Checkpoint inhibitor 
ECOG    Eastern Cooperative Oncology Group  
FOXP3    Forkhead box P3 
LATS2    Large Tumor Suppressor Kinase 2 
MHC     Major histocompatibility complex 
NF2     Neurofibromin 2 
PD-1     Programmed cell death protein 1 
PD-L1    Programmed cell death ligand 1 
SETD2    SET Domain Containing 2 
TMB     Tumour mutational burden 
TP53     Tumor protein p53 
VISTA    V-domain Ig suppressor of T cell activation 
WES     Whole exome sequencing 
WT1     Wilms tumor protein 1 
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Figure 1: 
A. Axial Enhanced Computer Tomography of thorax.  
Upper left panel (a): Baseline prior to commencing pembrolizumab trial (June 
2014) with left posterior parietal malignant pleural disease (white circle).  
Upper right panel (b): Maintained partial response after 52 cycles 
pembrolizumab (April 2016) with minimal residual pleural thickening (white 
arrow) 
Lower left panel (c): Disease progression (July  2018) at site of previous 
disease along the left posterior parietal pleura (white circle) 
Lower right panel (d): Partial response in left parietal posterior pleural 
disease  following 3 cycles pembrolizumab rechallenge 
B:Tumour response  
 
Figure 2.  
A. PD-L1 IHC by Dako 22C3 in baseline (left panel) and relapse (right panel) 
biopsy.  
B. CD3 by immunohistochemistry in baseline (left panel) and relapse (right 
panel) biopsy.  
 
Figure 3. Multi-coloured immunofluorescence panel for T-cells in baseline 
(upper panels) and relapse (lower panels) biopsy.  
 
Figure 4. Circos plot of CNA and somatic mutations. From outermost to 
innermost track: progression sample CNA (log2R), baseline sample CNA 
(log2R), progression sample mutations, baseline sample mutations 
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